Please assess the completion status of the following clinical trial:

Trial Title: Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a serious measurable neurological deficit on the NIH Stroke Scale due to focal brain ischemia.~* An NIH Stroke Scale score \>5 at the time the rt-PA is begun.~* Age: 18 through 85 years (i.e. candidates must have had their 18th birthday, but not had their 86th birthday).~* Intravenous rt-PA therapy must be initiated within 3 hours of onset of stroke symptoms.~Exclusion Criteria:~* History of stroke in the past 3 months.~* Previous intra-cranial hemorrhage, neoplasm, subarachnoid hemorrhage, or arterial venous malformation.~* Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT scan is normal.~* Hypertension at time of treatment; systolic BP \> 185 or diastolic \> 110 mmHg or aggressive measures to lower blood pressure to below these limits are needed.~* Presumed septic embolus.~* Presumed pericarditis including pericarditis after acute myocardial infarction.~* Recent (within 30 days) surgery or biopsy of parenchymal organ.~* Recent (within 30 days) trauma, with internal injuries or ulcerative wounds.~* Recent (within 90 days) severe head trauma or head trauma with loss of consciousness.~* Any active or recent (within 30 days) serious systemic hemorrhage.~* Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; or oral anticoagulant therapy with International Normalized Ratio (INR) \> 1.7.~* Baseline lab values: positive urine pregnancy test, glucose \< 50 or \> 400 mg/dl, platelets \<100,000 /mm3, Hct \<25 %, or creatinine \> 4 mg/dl.~* Ongoing renal dialysis, regardless of creatinine.~* Subjects who received Low Molecular Weight heparins (such as Dalteparin, Enoxaparin, Tinzaparin) as deep vein thrombosis (DVT) prophylaxis or in full dose within the previous 24 hours.~* Subjects who received heparin or a direct thrombin inhibitor (such as bivalirudin, argatroban, or lepirudin) within 48 hours from screening must have had a normal partial prothrombin time (PTT).~* Subjects who received Factor Xa inhibitors (such as fondaparinux) or direct thrombin inhibitors (such as dabigatran) within the last 4 days.~* Arterial puncture at a non-compressible site or a lumbar puncture in the previous 7 days.~* Seizure at onset of stroke.~* Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations.~* Other serious, advanced, or terminal illness or any other condition that the investigator feels would pose a significant hazard to the patient if rt-PA or eptifibatide therapy were initiated.~* Patients whose peripheral venous access is so poor that they are unable to have two standard peripheral intravenous lines started.~* Current participation in another research drug treatment protocol. Patient cannot start another experimental agent until after 90 days.~* Informed consent is not or cannot be obtained.~* Any known history of amyloid angiopathy.~* High density lesion consistent with hemorrhage of any degree.~* Significant mass effect with midline shift.~* Large (more than 1/3 of the middle cerebral artery) regions of clear hypodensity on the baseline CT scan. Sulcal effacement and/or loss of grey-white differentiation alone are not contraindications for treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Eptifibatide (Type: EXPERIMENTAL): All subjects will receive the standard dose of IV rt-PA. All subjects will promptly receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).